L-Type amino acid transporter 1 as a target for drug delivery
Our growing understanding of membrane transporters and their substrate specificity has opened a new avenue in the field of targeted drug delivery. The L-type amino acid transporter 1 (LAT1) has been one of the most extensively investigated transporters for delivering drugs across biological barriers...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
06 May 2020
|
| In: |
Pharmaceutical research
Year: 2020, Jahrgang: 37 |
| ISSN: | 1573-904X |
| DOI: | 10.1007/s11095-020-02826-8 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11095-020-02826-8
|
| Verfasserangaben: | Elena Puris, Mikko Gynther, Seppo Auriola, Kristiina M. Huttunen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1698938373 | ||
| 003 | DE-627 | ||
| 005 | 20230427031948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200528s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11095-020-02826-8 |2 doi | |
| 035 | |a (DE-627)1698938373 | ||
| 035 | |a (DE-599)KXP1698938373 | ||
| 035 | |a (OCoLC)1341326753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Puris, Elena |e VerfasserIn |0 (DE-588)1211100596 |0 (DE-627)1698938217 |4 aut | |
| 245 | 1 | 0 | |a L-Type amino acid transporter 1 as a target for drug delivery |c Elena Puris, Mikko Gynther, Seppo Auriola, Kristiina M. Huttunen |
| 264 | 1 | |c 06 May 2020 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.05.2020 | ||
| 520 | |a Our growing understanding of membrane transporters and their substrate specificity has opened a new avenue in the field of targeted drug delivery. The L-type amino acid transporter 1 (LAT1) has been one of the most extensively investigated transporters for delivering drugs across biological barriers. The transporter is predominantly expressed in cerebral cortex, blood-brain barrier, blood-retina barrier, testis, placenta, bone marrow and several types of cancer. Its physiological function is to mediate Na+ and pH independent exchange of essential amino acids: leucine, phenylalanine, etc. Several drugs and prodrugs designed as LAT1 substrates have been developed to improve targeted delivery into the brain and cancer cells. Thus, the anti-parkinsonian drug, L-Dopa, the anti-cancer drug, melphalan and the anti-epileptic drug gabapentin, all used in clinical practice, utilize LAT1 to reach their target site. These examples provide supporting evidence for the utility of the LAT1-mediated targeted delivery of the (pro)drug. This review comprehensively summarizes recent advances in LAT1-mediated targeted drug delivery. In addition, the use of LAT1 is critically evaluated and limitations of the approach are discussed. | ||
| 700 | 1 | |a Gynther, Mikko |e VerfasserIn |4 aut | |
| 700 | 1 | |a Auriola, Seppo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huttunen, Kristiina M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical research |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1984 |g 37(2020) Artikel-Nummer 88, 17 Seiten |h Online-Ressource |w (DE-627)325485291 |w (DE-600)2036232-8 |w (DE-576)104082380 |x 1573-904X |7 nnas |a L-Type amino acid transporter 1 as a target for drug delivery |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g extent:17 |a L-Type amino acid transporter 1 as a target for drug delivery |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s11095-020-02826-8 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200528 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1211100596 |a Puris, Elena |m 1211100596:Puris, Elena |d 160000 |d 160100 |e 160000PP1211100596 |e 160100PP1211100596 |k 0/160000/ |k 1/160000/160100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1698938373 |e 3673686895 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Puris","given":"Elena","roleDisplay":"VerfasserIn","display":"Puris, Elena","role":"aut"},{"given":"Mikko","family":"Gynther","role":"aut","display":"Gynther, Mikko","roleDisplay":"VerfasserIn"},{"given":"Seppo","family":"Auriola","role":"aut","roleDisplay":"VerfasserIn","display":"Auriola, Seppo"},{"given":"Kristiina M.","family":"Huttunen","role":"aut","roleDisplay":"VerfasserIn","display":"Huttunen, Kristiina M."}],"title":[{"title":"L-Type amino acid transporter 1 as a target for drug delivery","title_sort":"L-Type amino acid transporter 1 as a target for drug delivery"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 28.05.2020"],"recId":"1698938373","language":["eng"],"name":{"displayForm":["Elena Puris, Mikko Gynther, Seppo Auriola, Kristiina M. Huttunen"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"06 May 2020"}],"id":{"eki":["1698938373"],"doi":["10.1007/s11095-020-02826-8"]},"physDesc":[{"extent":"17 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"1984","publisher":"Springer Science + Business Media B.V ; Kluwer","dateIssuedDisp":"1984-","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]"}],"id":{"issn":["1573-904X"],"eki":["325485291"],"zdb":["2036232-8"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"L-Type amino acid transporter 1 as a target for drug deliveryPharmaceutical research","note":["Gesehen am 11.03.05"],"language":["eng"],"recId":"325485291","pubHistory":["1.1984 -"],"part":{"extent":"17","volume":"37","text":"37(2020) Artikel-Nummer 88, 17 Seiten","year":"2020"},"title":[{"title_sort":"Pharmaceutical research","title":"Pharmaceutical research"}]}]} | ||
| SRT | |a PURISELENALTYPEAMINO0620 | ||